(Q37087333)

English

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

scientific article published on February 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding (English)

1 reference

Europe PubMed Central

18 August 2017

1 reference

based on heuristic

inferred from title

author name string

Monica R McClain

1

1 reference

Europe PubMed Central

18 August 2017

Glenn E Palomaki

2

1 reference

Europe PubMed Central

18 August 2017

Margaret Piper

3

1 reference

Europe PubMed Central

18 August 2017

James E Haddow

4

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

1 February 2008

1 reference

Europe PubMed Central

18 August 2017

Genetics in Medicine

1 reference

Europe PubMed Central

18 August 2017

10

1 reference

Europe PubMed Central

18 August 2017

89-98

1 reference

Europe PubMed Central

18 August 2017

2

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1097/gim.0b013e31815bf924

0 references

Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Flow cytometric assay for genotyping cytochrome p450 2C9 and 2C19: comparison with a microelectronic DNA array.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Does anticoagulation do more harm than good?: A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Fixed minidose versus-adjusted low-dose warfarin after total joint arthroplasty: a randomized prospective study

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Interindividual variability in sensitivity to warfarin--Nature or nurture?

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Association between the CYP2C9 polymorphism and the drug metabolism phenotype

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Ethical implications of pharmacogenetics--do slippery slope arguments matter?

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Limitations of direct-to-consumer advertising for clinical genetic testing

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E31815BF924

21 January 2018

Identifiers

10.1097/GIM.0B013E31815BF924

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37087333&oldid=2102121696"